The Latest Regenerative Medicine Articles from Streetwise Reports


Cellular Therapy Co. Earns Rare Pediatric Disease Designation for Infant Congenital Heart Treatment

  ()
Shares of Longeveron Inc. traded 50% higher after the company reported that the U.S. FDA approved its Lomecel-B for Rare Pediatric Disease Designation to treat a rare and life-threatening defect in infants called Hypoplastic Left Heart Syndrome.

Showing Results: 1 to 4 of 4

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"RHT is rated an Immediate Buy here."
– Clive Maund, CliveMaund.com
"REYG reported first drill results of 7.85m of 3.95 g/t gold."
– Chen Lin, What Is Chen Buying? What Is Chen Selling?
"OCG discovered its 11th high grade vein at the Santa Ana project."
– Stuart McDougall, Research Capital Corporation